Contributed analysis
Approval is not access: Pilots' real test is implementation
In pharmaphorum, Varun Sharma argues that medicines access pilots should measure the full chain from recommendation to funded delivery and outcomes.
NEUVIOR summary
A national recommendation is one gate in a longer access pathway.
A medicine can be recommended nationally and remain difficult to reach when diagnostics, funding, local pathways, workforce, governance or monitoring are not ready.
Varun Sharma's pharmaphorum analysis argues that pilots should be judged by whether they expose and resolve those implementation dependencies, not by activity or approval alone.
Measure the complete implementation chain.
A useful access record separates regulatory authorisation, national recommendation, funded local availability, clinical offering, patient uptake, outcome monitoring and the recorded reason for delay. Collapsing those stages into one access claim hides where responsibility stops.
- Time from national recommendation to a funded, operational pathway
- Adjusted regional variation in access
- Diagnostic and pathway readiness
- Transparent governance of industry co investment
Use pilots to test delivery, not create theatre.
A pilot should reveal whether a pathway can identify eligible people, fund and offer the medicine, monitor what follows and retain accountable ownership. A launch event or small activity count cannot substitute for that operating evidence.
Make co investment visible and non promotional.
Infrastructure support can be useful when its purpose, governance, decision rights and evaluation are explicit. It should remain separated from prescribing, procurement and patient data decisions and be assessed against a public interest implementation objective.
Primary source context
- Read the pharmaphorum article
Publisher hosted contributed Views & Analysis, published 18 August 2026.